Three-month treatment response and exacerbation in chronic obstructive pulmonary disease

Jung Su Lee, Chin Kook Rhee, Kwang Ha Yoo, Ji Hyun Lee, Ho Il Yoon, Tae Hyung Kim, Woo Jin Kim, Jin Hwa Lee, Seong Yong Lim, Tai Sun Park, Jae Seung Lee, Sei Won Lee, Sang Do Lee, Yeon Mok Oh

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The aim of this study was to investigate relationships between acute exacerbation andForced Expiratory Volume 1 second (FEV1) improvement after treatment with combinedlong-acting beta-agonist (LABA) and inhaled corticosteroid (ICS) in patients with chronicobstructive pulmonary disease (COPD). A total of 137 COPD patients were classified asresponders or nonresponders according to FEV1 improvement after 3 months of LABA/ICStreatment in fourteen referral hospitals in Korea. Exacerbation occurrence in these twosubgroups was compared over a period of 1 yr. Eighty of the 137 COPD patients (58.4%)were classified as responders and 57 (41.6%) as nonresponders. Acute exacerbationsoccurred in 25 patients (31.3%) in the responder group and in 26 patients (45.6%) in thenonresponder group (P = 0.086). FEV1 improvement after LABA/ICS treatment was asignificant prognostic factor for fewer acute exacerbations in a multivariate Coxproportional hazard model adjusted for age, sex, FEV1, smoking history, 6 min walkdistance, body mass index, exacerbation history in the previous year, and dyspnea scale.Three-month treatment response to LABA/ICS might be a prognostic factor for theoccurrence of acute exacerbation in COPD patients.

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalJournal of Korean Medical Science
Volume30
Issue number1
DOIs
StatePublished - 2015

Bibliographical note

Publisher Copyright:
© 2015 The Korean Academy of Medical Sciences.

Keywords

  • Disease progression
  • Forced expiratory volume
  • Pulmonary disease, chronic obstructive

Fingerprint

Dive into the research topics of 'Three-month treatment response and exacerbation in chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this